06.09.2018 • News

Evonik Sells US Jayhawk Site to Permira

Evonik Sells US Jayhawk Site to Permira (c) Evonik
Evonik Sells US Jayhawk Site to Permira (c) Evonik

Evonik is selling its Jayhawk site in Galena, Kansas, USA, as it takes the next step to focus on specialty chemicals. The German group has agreed a share deal under which funds advised by investment firm Permira will acquire the site along with the company and its staff of about 120 people, for a high double-digit million dollar sum.

The transaction remains subject to approval by antitrust authorities in several countries.

Jawhawk’s activities fall under the agrochemicals & polymer additives business line in Evonik’s Performance Materials segment and the site produces precursors for agrochemicals, which are not included in the growth business defined by Evonik.

“We want to continue growing profitably in the specialty chemicals sector,” said Evonik’s CEO Christian Kullmann. “This also means giving up businesses or sites if a different owner can offer the business better future perspectives. The sale is a further step towards optimizing our portfolio, and it opens up new opportunities for us in the targeted development of our growth engines.”

Sebastian Hoffmann, principal and member of the Industrials Team at Permira, said a strategic cooperation between Jayhawk and CABB, one of the private equity firm’s portfolio companies based in Sulzbach, Germany, would create a “seamless transatlantic product and service offering.”

Permia bought fine and specialty chemicals manufacturer CABB International in 2014 for €819 million. CABB was originally established in 2003 through the reorganization of Clariant’s acetyls operations.

Company

CABB Group GmbH

Otto-Volger-Straße 3c
65843 Sulzbach am Taunus

Company contact







From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.